The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB)

Introduction Patients with systemic lupus erythematosus (SLE) have increased cardiovascular risk related to lipid changes induced by inflammatory activity, proteinuria and treatments. Our objective was to analyse lipid changes in a cohort of patients with SLE resistant to standard treatments who wer...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lupus 2014-09, Vol.23 (10), p.1014-1022
Hauptverfasser:	Fernández-Nebro, A, Marenco, JL, López-Longo, F, Galindo, M, Hernández-Cruz, BE, Narváez, J, Rúa-Figueroa, Í I, Raya-Alvarez, E, Zea, A, Freire, M, Sánchez-Atrio, AI, García-Vicuña, R, Pego-Reigosa, JM, Manrique-Arija, S, Nieves-Martín, L, Carreño, L
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal, Murine-Derived - therapeutic use Biomarkers - blood Cholesterol Disease Drug dosages Dyslipidemias - blood Dyslipidemias - diagnosis Dyslipidemias - drug therapy Dyslipidemias - epidemiology Female High density lipoprotein Humans Linear Models Lipids Lipids - blood Lipoproteins Longitudinal Studies Lupus Lupus Erythematosus, Systemic - blood Lupus Erythematosus, Systemic - diagnosis Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - epidemiology Male Middle Aged Patients Retrospective Studies Rheumatology Risk Factors Rituximab Severity of Illness Index Spain - epidemiology Time Factors Treatment Outcome Triglycerides Tumor necrosis factor-TNF Variables
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!